CHMP recommends approval of Yselty for uterine fibroids.- ObsEva
Yselty is a selective, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to the GnRH receptors in the pituitary gland, modulating the hypothalamic-pituitary-gonadal axis. Yselty can be administered with or without concomitant hormonal add-back therapy depending on the clinical setting. As uterine fibroids are associated with heavy menstrual bleeding, the main benefit of Yselty is a reduced monthly blood loss. The most common side effects are hot flushes and headaches.
The full indication is: Yselty is indicated for treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins